SGI
ANIK icon

Summit Global Investments’s Anika Therapeutics ANIK Stock Holding History

Summit Global Investments’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,500
Closed -$330K – 529
2023
Q1 		$330K Buy
+11,500
New +$342K 0.03% 407

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Global Investments's ANIK Position: Q2 2023 in Review

Summit Global Investments sold out of Anika Therapeutics (ANIK) in Q2 2023, closing a stake of 11,500 shares — an estimated $330K sold.

Summit Global Investments first reported a position in ANIK in Q1 2023 and held it in 1 quarter. The position peaked at $330K in Q1 2023. 117 funds tracked by Wall St. Rank hold ANIK as of Q2 2023.

  • Summit Global Investments reported no remaining Anika Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Summit Global Investments sold 11,500 Anika Therapeutics shares in Q2 2023, an estimated $330K.
  • Summit Global Investments first reported a position in Anika Therapeutics in Q1 2023 and held it in 1 quarter.
  • Summit Global Investments's Anika Therapeutics position peaked at $330K in Q1 2023.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2023.

Based on Summit Global Investments's 13F filing for Q2 2023, filed 19 Jul 2023.